by admin | Oct 5, 2021 | Press Release
Project to support full Phase 2 trial, GMP manufacturing scale-up Seattle, WA, October 6, 2021 – Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced new development funding from the US...
by admin | Sep 22, 2021 | News
Listen now
by admin | Aug 31, 2021 | Press Release
— First-in-human trial studying LMN-201 enteric capsules underway in Australia Seattle, WA, September 1, 2021 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the start of a Phase 1...
by admin | Aug 27, 2021 | News
Antibody therapeutics revolutionised how diseases like cancer are treated in the developed world, but their high manufacturing cost and cumbersome distribution and administration leave them out of reach for most. In this guest article, Lumen Bioscience’s CEO, Brian...
by admin | Aug 11, 2021 | News
Today Lumen announced the first results of our long-running collaboration with Google’s world-beating AI/ML (machine learning) team. The gist: advanced algorithms helped us navigate a dizzying amount of data to double the productivity of cGMP biologics manufacturing...
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases